Middleton & Co Inc MA boosted its holdings in shares of Danaher Corporation (NYSE:DHR) by 8.0% in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 159,944 shares of the conglomerate’s stock after purchasing an additional 11,810 shares during the period. Danaher Corporation comprises approximately 2.5% of Middleton & Co Inc MA’s investment portfolio, making the stock its 5th biggest holding. Middleton & Co Inc MA’s holdings in Danaher Corporation were worth $13,720,000 as of its most recent SEC filing.
Other hedge funds and other institutional investors have also bought and sold shares of the company. GQG Partners LLC acquired a new position in Danaher Corporation during the second quarter valued at $101,000. Proficio Capital Partners LLC lifted its position in Danaher Corporation by 92.3% during the first quarter. Proficio Capital Partners LLC now owns 1,246 shares of the conglomerate’s stock valued at $105,000 after purchasing an additional 598 shares during the period. Monetary Management Group Inc. lifted its position in Danaher Corporation by 10.7% during the second quarter. Monetary Management Group Inc. now owns 1,550 shares of the conglomerate’s stock valued at $131,000 after purchasing an additional 150 shares during the period. Acrospire Investment Management LLC lifted its position in Danaher Corporation by 185.5% during the second quarter. Acrospire Investment Management LLC now owns 1,693 shares of the conglomerate’s stock valued at $143,000 after purchasing an additional 1,100 shares during the period. Finally, ClariVest Asset Management LLC acquired a new position in Danaher Corporation during the first quarter valued at $157,000. Institutional investors own 75.38% of the company’s stock.
A number of research firms recently issued reports on DHR. Goldman Sachs Group, Inc. (The) restated a “neutral” rating and set a $83.00 target price on shares of Danaher Corporation in a research report on Tuesday, September 26th. Jefferies Group LLC restated a “buy” rating and set a $95.00 target price on shares of Danaher Corporation in a research report on Friday, August 4th. BidaskClub downgraded shares of Danaher Corporation from a “sell” rating to a “strong sell” rating in a research report on Tuesday, August 1st. Zacks Investment Research downgraded shares of Danaher Corporation from a “buy” rating to a “hold” rating in a research report on Thursday, July 27th. Finally, Robert W. Baird boosted their target price on shares of Danaher Corporation from $87.00 to $97.00 and gave the company an “outperform” rating in a research report on Friday, October 20th. One research analyst has rated the stock with a sell rating, four have issued a hold rating, thirteen have assigned a buy rating and one has issued a strong buy rating to the stock. Danaher Corporation currently has a consensus rating of “Buy” and an average target price of $93.31.
COPYRIGHT VIOLATION NOTICE: “Middleton & Co Inc MA Boosts Position in Danaher Corporation (DHR)” was first reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are viewing this report on another site, it was illegally copied and reposted in violation of United States and international copyright and trademark law. The legal version of this report can be read at https://www.dispatchtribunal.com/2017/11/19/middleton-co-inc-ma-boosts-position-in-danaher-corporation-dhr.html.
In other news, SVP Daniel Raskas sold 37,870 shares of the business’s stock in a transaction dated Thursday, November 16th. The shares were sold at an average price of $93.33, for a total transaction of $3,534,407.10. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Thomas Patrick Joyce, Jr. sold 125,989 shares of the company’s stock in a transaction dated Wednesday, November 1st. The shares were sold at an average price of $92.64, for a total transaction of $11,671,620.96. Following the sale, the chief executive officer now directly owns 271,737 shares of the company’s stock, valued at approximately $25,173,715.68. The disclosure for this sale can be found here. Insiders have sold 317,498 shares of company stock valued at $28,838,801 in the last three months. Corporate insiders own 12.20% of the company’s stock.
Shares of Danaher Corporation (DHR) opened at $93.30 on Friday. The company has a market cap of $64,899.95, a PE ratio of 23.98, a PEG ratio of 2.22 and a beta of 1.02. The company has a debt-to-equity ratio of 0.42, a quick ratio of 1.00 and a current ratio of 1.43. Danaher Corporation has a one year low of $76.27 and a one year high of $93.86.
Danaher Corporation (NYSE:DHR) last released its earnings results on Thursday, October 19th. The conglomerate reported $1.00 EPS for the quarter, topping analysts’ consensus estimates of $0.95 by $0.05. The business had revenue of $4.53 billion during the quarter, compared to analysts’ expectations of $4.47 billion. Danaher Corporation had a net margin of 13.36% and a return on equity of 11.29%. The company’s quarterly revenue was up 9.6% on a year-over-year basis. During the same quarter in the previous year, the company earned $0.87 earnings per share. research analysts forecast that Danaher Corporation will post 3.99 EPS for the current fiscal year.
The business also recently announced a quarterly dividend, which was paid on Friday, October 27th. Stockholders of record on Friday, September 29th were paid a dividend of $0.14 per share. The ex-dividend date of this dividend was Thursday, September 28th. This represents a $0.56 dividend on an annualized basis and a dividend yield of 0.60%. Danaher Corporation’s dividend payout ratio is currently 16.52%.
Danaher Corporation Company Profile
Danaher Corporation (Danaher) designs, manufactures and markets professional, medical, industrial and commercial products and services. The Company operates through four segments: Life Sciences, which offers a range of research tools that scientists use to study the basic building blocks of life, including genes, proteins, metabolites and cells, in order to understand the causes of disease, identify new therapies and test new drugs and vaccines; Diagnostics; which offers analytical instruments, reagents, consumables, software and services; Dental, which provides products that are used to diagnose, treat and prevent disease and ailments of the teeth, gums and supporting bone, and Environmental & Applied Solutions, which consists of various lines of business, including water quality and product identification.
Receive News & Ratings for Danaher Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Danaher Corporation and related companies with MarketBeat.com's FREE daily email newsletter.